A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

@article{Ramalingam2015ARP,
  title={A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).},
  author={Suresh S Ramalingam and Glenwood D Goss and Rafael Rosell and Gerald Schmid-Bindert and Bojan Zaric and Zoran Gojko Andric and Igor M. Bondarenko and Dmitry Komov and Timur Ceri{\'c} and Fadlo R. Khuri and Miroslav Samar{\vz}ija and E Felip and Tudor Eliade Ciuleanu and Vera Hirsh and Thomas C. Wehler and James F. Spicer and Ravi Salgia and Geoffrey I. Shapiro and Eric Sheldon and Florentina Teofilovici and Vojo M Vukovic and D. A. Fennell},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 8},
  pages={1741-8}
}
BACKGROUND This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. PATIENTS AND METHODS Patients with one prior systemic therapy for advanced disease were eligible. Docetaxel (75 mg/m(2) on day 1) was administered alone or with ganetespib (150 mg/m(2) on days 1 and 15) every 3 weeks. The primary end points were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3

  • GP Nagaraju, W Park, J Wen
  • Angiogenesis
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…